证券代码：600998 证券简称：九州通 公告编号：临 2026-008 九州通医药集团股份有限公司 关于2026年度第一期科技创新债券发行结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 九州通医药集团股份有限公司（以下简称"公司"）于2024年1月5日召开2024 年第一次临时股东会，审议通过了《关于公司申请注册发行直接债务融资工具及 相关事宜的议案》，同意公司在股东会批准的额度范围内发行直接债务融资工具， 注册发行种类包括但不限于中国境内市场的超短期融资券、短期融资券等，在注 册有效期（2年）内分期择机发行（详见公告编号：临2024-001）。2025年12月17 日，公司收到中国银行间市场交易商协会签发的《接受注册通知书》（中市协注 〔2025〕SCP375号），接受注册金额为30亿元，注册额度自上述通知书落款之 日起2年内有效（详见公告编号：临2025-089）。 截至本公告披露日，公司累计发行超短期融资券余额为人民币 3 亿元。 特此公告。 九州通医药集团股份有限公司董事会 一、本次科技创新债券发行结果情 ...

证券代码：600998 证券简称：九州通 公告编号：临 2026-007 九州通医药集团股份有限公司 关于控股股东及其一致行动人提前解除股份质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●公司控股股东楚昌投资及其一致行动人中山广银分别办理完成17,980,000股和 49,020,000股的股份提前解除质押手续，本次提前解除质押股份占其所持股份的比例分 别为3.91%和14.62%，占公司总股本的比例分别为0.36%和0.97%。同时，中山广银办理 完成64,600,000股的股份质押手续，本次质押股份占其所持股份的比例为19.26%，占公 司总股本的比例为1.28%。 ●截至2026年1月21日，公司控股股东楚昌投资及其一致行动人中山广银分别持有公 司股份459,506,100股和335,357,275股，占公司总股本的比例分别为9.11%和6.65%。本次 股份提前解除质押及质押办理完成后，楚昌投资和中山广银分别累计质押公司股份 215,850,980股和335,276,820股，占公司 ...

Group 1 - The core point of the article highlights that Jiuzhoutong (600998) reported a closing price of 5.25 yuan on January 16, 2026, with a decline of 2.78% and a trading volume of 683,000 hands, resulting in a transaction amount of 361 million yuan [1][3] Group 2 - On January 16, the net outflow of main funds was 1.9196 million yuan, accounting for 0.53% of the total transaction amount, while the net inflow of speculative funds was 1.9251 million yuan, also accounting for 0.53% [1][3] - Retail investors experienced a net outflow of 0.55 million yuan, which is negligible compared to the total transaction amount [1] Group 3 - Jiuzhoutong provided guarantees totaling 4.88113 billion yuan for 54 subsidiaries, with 3.23613 billion yuan allocated to subsidiaries with a debt-to-asset ratio exceeding 70% [1][3] - The total amount of external guarantees as of December 31, 2025, was 29.1361262 billion yuan, representing 106.95% of the most recent audited net assets, with no overdue guarantees [1] Group 4 - In the fourth quarter of 2025, Jiuzhoutong's highest balance for entrusted wealth management was 1.4 billion yuan, all of which was invested in treasury bond reverse repurchase products [1][3] - The entrusted wealth management balance was zero at the end of the fourth quarter of 2025, and the investment scope focused on high safety and liquidity products [1]

证券代码：600998 证券简称：九州通 公告编号：临 2026-005 九州通医药集团股份有限公司 公司委托理财的投资范围主要是安全性高、流动性好的理财产品，主要风险 包括市场波动风险、宏观经济形势及货币政策、财政政策等宏观政策发生变化带 来的系统性风险等，委托理财的实际收益存在不确定性，敬请广大投资者注意投 资风险。 一、投资情况概述 关于 2025 年第四季度委托理财情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基本情况 | 投资金额 | 140,000.00 | 万元 | | | --- | --- | --- | --- | | 投资种类 | 国债逆回购 | | | | 投资期限 | 期限为 7 | 天、4 | 天、3 天、2 天 | | 资金来源 | 自有资金 | | | 投资金额为 2025 年第四季度存续的委托理财最高余额。截至 2025 年第四季 度末，委托理财余额为 0 元。 已履行的审议程序 九州通医药集团股份有限公司（以下简称"公司"）于 2024 年 12 月 8 日和 ...

证券代码：600998 证券简称：九州通 公告编号：临 2026-006 九州通医药集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | 本次担保 | 实际为其提供的担 保余额（不含本次担 | 是否在前期预 | 本次担保是 | | --- | --- | --- | --- | --- | | | 金额 | 保金额） | 计额度内 | 否有反担保 | | 重庆九州通医药有限 公司、内蒙古九州通 | 488,113.00 | 1,772,074.00 | 是 | 是 | | 医药有限公司等 54 家 | 万元 | 万元 | | | | 子公司 | | | | | 累计担保情况 | 对外担保逾期的累计金额（万 | 0.00 | | --- | --- | | 元） | | | 截至本公告日上市公司及其控 | 2,913,612.62 | | 股子公司对外担保总额（万元） | | | 对外担保总额占上市公司最近 一期经审计净资产的比 ...

Group 1 - The 2026 Beijing Commercial Brand Conference and the announcement of the 2025 Top Ten Commercial Brands took place in Beijing, focusing on the theme "New Demand, New Supply" [1] - The event was guided by the Beijing Municipal Bureau of Commerce and co-hosted by Beijing Daily Media Group and Beijing Commercial Association, showcasing the highest level of commercial brands in Beijing [1] - Ten brands were recognized as the "2025 Beijing Commercial Quality Service Brands," including 58 Tongcheng, Chaoyang Joy City, Dingdong Maicai, Dongfang Zhenxuan, Haidilao, Juran Home, Jiuzhoutong, Lao Chuan Ban, Vipshop, and Yunda Express [1] Group 2 - The main list of the "2025 Top Ten Commercial Brands" reflects brands with significant market influence and leadership in industry development [4] - Four permanent sub-lists were introduced: "Beijing Commercial Quality Service Brands," "Beijing Commercial Model Innovation Brands," "Beijing Commercial Craftsmanship Brands," and "Beijing Commercial New Star Brands" [4] - Three new special annual lists were introduced for the first time, including "Outstanding Cases of Financial Product Innovation Empowering Consumption," "Outstanding Cases of Cultural, Business, Tourism, and Sports Integration in Beijing," and "Leading Brands in Beijing's Fashion Consumption Power" [4]

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.19% on January 15, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Individual Stock Performance - Notable gainers included: - RunDa Medical (603108) with a closing price of 20.04, up 1.83% and a trading volume of 700,800 shares [1] - LiuYao Group (603368) closed at 18.58, up 0.60% with a trading volume of 79,700 shares [1] - LaoBaiXing (603883) closed at 16.11, up 0.50% with a trading volume of 226,200 shares [1] - Significant decliners included: - Huaren Health (301408) closed at 23.81, down 19.99% with a trading volume of 491,100 shares [2] - ShangYu PingMin (301017) closed at 18.50, down 13.75% with a trading volume of 373,900 shares [2] - YaoYiGou (300937) closed at 37.40, down 11.79% with a trading volume of 121,400 shares [2] Capital Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 990 million yuan from institutional investors, while retail investors had a net inflow of 977 million yuan [2] - The table of capital flow indicates that: - LaoBaiXing (603883) had a net inflow of 46.10 million yuan from institutional investors [3] - JiuZhouTong (600998) had a net inflow of 40.43 million yuan from institutional investors [3] - RunDa Medical (603108) had a net inflow of 37.80 million yuan from institutional investors [3]

Core Viewpoint - Tianjin Jiuan Medical Electronics Co., Ltd. has recently acquired a piece of industrial land in Nankai District, marking it as the fourth industrial land transaction in the area since 2025, following companies like Jiuzhoutong Pharmaceutical Group and Aier Eye Hospital Group [1] Group 1: Industrial Land Development - Nankai District is focusing on simultaneous promotion of investment attraction and revitalization of idle assets, aiming to gather the development of science and technology innovation industries [1] - The district's strategy includes optimizing spatial layout into a "one core, two axes, three zones" structure, with the Tiankai Higher Education Science and Technology Innovation Park as the innovation engine [1] Group 2: Modern Industrial System - Nankai District has proposed a "3+2" modern urban industrial system, emphasizing three main industries: technology services, intelligent manufacturing, and biomedicine, along with two characteristic industries: cultural tourism and commercial services [2] - The technology service sector will leverage resources from universities and key laboratories to create a comprehensive service system covering R&D, technology transfer, concept validation, intellectual property, and technology finance [2]

Group 1 - Tianjin Jiuan Medical Electronics Co., Ltd. has recently acquired an industrial land in Nankai District, marking it as the fourth industrial land transaction in the area since 2025, following companies like Jiuzhoutong Pharmaceutical Group and Aier Eye Hospital Group [1] - Nankai District is focusing on synchronizing investment attraction and revitalization efforts to enhance the development of the science and technology innovation industry [1] - The district aims to optimize its spatial layout into a structure of "one core, two axes, and three zones," with the Tiankai Higher Education Science and Technology Innovation Park as the innovation engine [1] Group 2 - Nankai District has proposed to develop a "3+2" modern urban industrial system, focusing on three main industries: technology services, intelligent manufacturing, and biomedicine, along with two characteristic industries: cultural tourism and commercial services [2] - The district plans to accelerate the transformation of old and new driving forces by strengthening its leading industries and nurturing future industries [2] - The technology service industry will leverage resources from universities and key laboratories to create a comprehensive service system covering research and development, technology transfer, concept validation, intellectual property, and technology finance [2]

Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]